TY - JOUR
KW - Analgesics, Opioid/therapeutic use
KW - Buprenorphine/therapeutic use
KW - Capacity Building
KW - Health Services Needs and Demand/statistics & numerical data
KW - Health Surveys
KW - Humans
KW - Methadone/therapeutic use
KW - Opiate Substitution Treatment/statistics & numerical data
KW - Opioid-Related Disorders/drug therapy/epidemiology
KW - United States/epidemiology
AU - C. M. Jones
AU - M. Campopiano
AU - G. Baldwin
AU - E. McCance-Katz
A1 - 
AB - OBJECTIVES: We estimated national and state trends in opioid agonist medication-assisted treatment (OA-MAT) need and capacity to identify gaps and inform policy decisions. METHODS: We generated national and state rates of past-year opioid abuse or dependence, maximum potential buprenorphine treatment capacity, number of patients receiving methadone from opioid treatment programs (OTPs), and the percentage of OTPs operating at 80% capacity or more using Substance Abuse and Mental Health Services Administration data. RESULTS: Nationally, in 2012, the rate of opioid abuse or dependence was 891.8 per 100 000 people aged 12 years or older compared with national rates of maximum potential buprenorphine treatment capacity and patients receiving methadone in OTPs of, respectively, 420.3 and 119.9. Among states and the District of Columbia, 96% had opioid abuse or dependence rates higher than their buprenorphine treatment capacity rates; 37% had a gap of at least 5 per 1000 people. Thirty-eight states (77.6%) reported at least 75% of their OTPs were operating at 80% capacity or more. CONCLUSIONS: Significant gaps between treatment need and capacity exist at the state and national levels. Strategies to increase the number of OA-MAT providers are needed.
BT - American Journal of Public Health
C5 - Opioids & Substance Use; Healthcare Policy
CP - 8
CY - United States
DO - 10.2105/AJPH.2015.302664
IS - 8
JF - American Journal of Public Health
N2 - OBJECTIVES: We estimated national and state trends in opioid agonist medication-assisted treatment (OA-MAT) need and capacity to identify gaps and inform policy decisions. METHODS: We generated national and state rates of past-year opioid abuse or dependence, maximum potential buprenorphine treatment capacity, number of patients receiving methadone from opioid treatment programs (OTPs), and the percentage of OTPs operating at 80% capacity or more using Substance Abuse and Mental Health Services Administration data. RESULTS: Nationally, in 2012, the rate of opioid abuse or dependence was 891.8 per 100 000 people aged 12 years or older compared with national rates of maximum potential buprenorphine treatment capacity and patients receiving methadone in OTPs of, respectively, 420.3 and 119.9. Among states and the District of Columbia, 96% had opioid abuse or dependence rates higher than their buprenorphine treatment capacity rates; 37% had a gap of at least 5 per 1000 people. Thirty-eight states (77.6%) reported at least 75% of their OTPs were operating at 80% capacity or more. CONCLUSIONS: Significant gaps between treatment need and capacity exist at the state and national levels. Strategies to increase the number of OA-MAT providers are needed.
PP - United States
PY - 2015
SN - 1541-0048; 0090-0036
EP - 63
EP - e55+
T1 - National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment
T2 - American Journal of Public Health
TI - National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment
U1 - Opioids & Substance Use; Healthcare Policy
U2 - 26066931
U3 - 10.2105/AJPH.2015.302664
VL - 105
VO - 1541-0048; 0090-0036
Y1 - 2015
ER -